Wells Fargo & Company MN Acquires 19,893 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wells Fargo & Company MN increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 687,824 shares of the medical research company’s stock after buying an additional 19,893 shares during the period. Wells Fargo & Company MN owned 0.11% of Edwards Lifesciences worth $52,447,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares during the period. Telos Capital Management Inc. boosted its holdings in Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC boosted its holdings in Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP boosted its holdings in Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 2,043 shares during the period. Finally, HealthInvest Partners AB bought a new position in Edwards Lifesciences in the 4th quarter valued at $1,587,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EW. Oppenheimer lifted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Citigroup raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $98.00 to $105.00 in a report on Wednesday. Mizuho lifted their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Finally, Royal Bank of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $94.31.

Edwards Lifesciences Price Performance

EW stock opened at $87.98 on Friday. The firm’s 50-day moving average price is $89.68 and its two-hundred day moving average price is $81.63. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock has a market capitalization of $53.02 billion, a price-to-earnings ratio of 37.92, a PEG ratio of 3.22 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $85.59, for a total transaction of $620,955.45. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,632,543.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $85.59, for a total transaction of $620,955.45. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,632,543.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernard J. Zovighian purchased 580 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 180,707 shares of company stock worth $16,034,814 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.